Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Invested Capital: 2022-2025

Historic Invested Capital for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $13.4 million.

  • InMed Pharmaceuticals' Invested Capital rose 38.06% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 38.06%. This contributed to the annual value of $13.4 million for FY2025, which is 45.93% up from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Invested Capital is $13.4 million, which was up 45.93% from $9.2 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Invested Capital ranged from a high of $13.4 million in FY2025 and a low of $9.1 million during FY2022.
  • In the last 3 years, InMed Pharmaceuticals' Invested Capital had a median value of $12.1 million in 2023 and averaged $11.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first decreased by 23.85% in 2024, then surged by 45.93% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Invested Capital (MRY) stood at $9.1 million in 2022, then surged by 33.17% to $12.1 million in 2023, then fell by 23.85% to $9.2 million in 2024, then skyrocketed by 45.93% to $13.4 million in 2025.
  • Its Invested Capital stands at $13.4 million for FY2025, versus $9.2 million for FY2024 and $12.1 million for FY2023.